Abbott RealTime HCV Genotype II

For more information, contact Abbott.

Contact
Product Description
SPECIFICATIONS
Product Description

Indications and Limitations of Use

Intended Use

The Abbott RealTime HCV Genotype II is an in vitro reverse transcription-polymerase chain reaction (RT-PCR) assay for use with the Abbott mSample Preparation System reagents and with the Abbott m2000sp and m2000rt instruments for the qualitative identification of hepatitis C virus (HCV) genotypes 1, 1a, 1b, and 2 -5 in plasma or serum from individuals chronically infected with HCV. The Abbott RealTime HCV Genotype II is intended for use as an aid in the management of HCV-infected individuals and in guiding the selection of therapeutic treatment indicated for the above listed genotypes. The assay is intended for use on patients who are chronically infected with HCV, are being considered for antiviral treatment, and are positive for HCV RNA. The Abbott RealTime HCV Genotype II assay is not for screening blood, plasma, serum or tissue donors for HCV.

Limitations of the Procedure

  • FOR IN VITRO DIAGNOSTIC USE ONLY.
  • Optimal performance of this test requires appropriate specimen collection, handling, preparation, storage, and transport to the test site (refer to the SPECIMEN COLLECTION, STORAGE, ANDTRANSPORT TO THE TEST SITE section of this package insert).
  • Human serum or plasma (ACD-A, CPD, potassium EDTA, or sodium EDTA) specimens may be used with the Abbott RealTime HCV Genotype II assay. The use of other anticoagulants has not been validated with the Abbott RealTime HCV Genotype II assay.
  • Use of the Abbott RealTime HCV Genotype II assay is limited to personnel who have been trained in the procedures of a molecular diagnostic assay and the Abbott m2000sp and m2000rt instruments.
  • The instruments and assay procedures reduce the risk of contamination by amplification product. However, nucleic acid contamination from the positive control or specimens must be controlled by good laboratory practice and careful adherence to the procedures specified in this package insert.
  • A specimen with an interpretation of “No Genotype Result” cannot be presumed to be negative for the tested genotypes.
  • Multiple genotype assay results may be caused by a mixed genotype infection, recombination of HCV genotypes, or assay probe cross-reactivity.
  • The Abbott RealTime HCV Genotype II assay is capable of detecting both genotypes in a genotype mixture when the concentrations of both genotypes are near equal; however, the assay may not detect the lower concentration genotype.
  • Performance has not been established with the Abbott RealTime HCV Genotype II assay for HCV genotype 6 specimens.
  • HCV genotype 6 specimens may generate a HCV genotype 1 result with the Abbott RealTime HCV Genotype II assay based on probe cross-reactivity of the HCV genotype 1 probe.
  • As with any diagnostic test, results from the Abbott RealTime HCV Genotype II assay should be interpreted in conjunction with other clinical and laboratory findings. A specimen with a result of "HCV not detected" cannot be presumed to be negative for HCV RNA.
  • Contamination from HCV positive controls and clinical specimens can be avoided only by good laboratory practices and careful adherence to the procedures specified in this package insert.

CAUTION: United States Federal law restricts this device to sale and distribution to or on the order of a physician or to a clinical laboratory; and use is restricted to, by, or on the order of a physician.

To learn more about RealTime HCV Genotype II please visit: https://www.molecular.abbott/us/en/products/infectious-disease/realtime-hcv-genotype-II

SPECIFICATIONS
Abbott RealTime HCV Genotype II assay performance
Target Regions 5'UTR for GT 1-5, NS5b for subtypes 1a, 1b
Limit of Detection 500 IU/mL
Accuracy 99.5% compared to sequencing
Specificity 100%*
Standardization Second World Health Organization International Standard for Hepatitis C Virus RNA
Internal Control Yes; processed through sample prep with each sample
External Control Yes; Negative, Positive
Results Reported Qualitative - Genotype Call
Specimen Type Serum or plasma (ACD-A, CPD, potassium EDTA, or sodium EDTA)
Process Time 5.5 hours (24 tests)
*Performance of Abbott RealTime HCV Genotype II with HCV negative specimens was evaluated by analyzing 370 unique HCV negative specimens; 135 HCV serologically-negative serum and 235 HCV serologically-negative plasma specimens. The observed specificity was 100% (370/370).

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No